Kornimate/medical-research-clean huggingface dataset:
active ingredients & efficacy of aquatic therapy for autistic children

Conditions: Autism Spectrum Disorder

Summary: accidental drowning is the number one cause of death in children with autism spectrum disorders (asd) and highlights the critical need for swim lessons and water safety training for this population. our team has developed and tested an innovative, occupational therapy (ot) based aquatic program - aquotic - that provides preliminary support for the use of an individualized swim skills training intervention in children with asd. the aquotic program uses a combination of sensory, motor learning, and behavioral approaches to improve water safety and swim skills. in this study, we will use a randomized control trial design to identify the efficacy of the aquotic intervention to improve swim performance in children with asd.

once enrolled, children will be randomized to one of three groups. group a will receive the intervention right away. group b will use a waitlist control for 10 weeks, then will receive the intervention. group c will be a control group, and will be offered the intervention at the end of the control period. each group will have 12 participants. aquotic a group based aquatic occupational therapy intervention that uses evidence-based therapeutic teaching techniques including therapeutic relationship, grading of activities, shaping, positive reinforcement and individualized goals to direct the intervention. we will also develop a fidelity measure to operationalize the therapeutic strategies and quantify the active ingredients of the aquotic program. our long-term goal is to create evidence for an ot-based swim intervention for children with asd that has the potential to decrease the drowning risk in this population.

Eligibility criteria:
inclusion criteria: * pre-existing diagnosis of autism \& interest in learning to swim exclusion criteria: * able to float or move through the water for 5-10 feet without assistance. * presence of compromised airway such as trachea or ventilation system * other contraindication to submersion in water.
prognosis of patients with acute-on-chronic liver failure

Conditions: Acute-On-Chronic Liver Failure

Summary: patients with acute on chronic liver failure (aclf) have high short-term mortality. the use of a severity score could define the patient's prognosis. this study mainly prospectively analyze the clinical data of patients with chronic liver disease related acute liver failure admitted to the department of infectious diseases, xiangya hospital of central south university, to analyze the prognosis of patients with chronic liver disease related acute on-chronic liver failure in central south china. no additional interventions other than routine treatment will be added.

patients with acute on chronic liver failure (aclf) have high short-term mortality. the use of a severity score could define the patient's prognosis and would help determine in whom the treatment is effective. this study mainly prospectively analyze the clinical data of patients with chronic liver disease related acute liver failure admitted to the department of infectious diseases, xiangya hospital of central south university, to analyze the short-time and relatively long-term prognosis of patients with chronic liver disease related acute on-chronic liver failure. this is an observational study. all subjects will receive the currently recognized routine treatment of liver failure and corresponding etiological treatment if needed. the researchers will collect various clinical examination indexes of the subjects in the process of diagnosis and treatment, including but not limited to blood routine, biochemistry, coagulation function, liver imaging, therapeutic drugs, etc. complications and prognosis of patients will be recorded. blood samples, urine and stool samples of all subjects will be taken after enrollment and stored for probably testing in the future. this study has no additional intervention and treatment for subjects. all subjects will sign informed consent.

Eligibility criteria:
inclusion criteria: * patients with evidence of chronic liver disease patients with liver failure exclusion criteria: * patients who do not have chronic liver disease patients who have hepatocellular carcinoma patients who admitted for extrahepatic manifestations patients who have hiv infection patients who admitted for symptomatic control of chronic liver disease, other than acute deterioration of liver function
vegetables intake and polymorphism tas2r38 gene by healthy adults

Conditions: Healthy Lifestyle; Taste Disorders; Diet Habit

Summary: personalized nutrition is one of the most up to date trends in human nutrition and gains much interest of general public and scientists as well. although we have gained some knowledge on gene-trait associations, the real effectiveness and usefulness of genotype-based nutritional recommendations is unknown. many personalized nutrition companies are on the market today, some of them use personalized nutrition based on genotype analysis. for this reason, scientific basis of this approach should be clarified. our project can thus increase knowledge which can be applied in dietary counseling practice. although we focus on increase vegetable and fruits intake, the study is designed as a proof of concept.

in humans, the tas2r38 receptor gene is responsible for differences in the perception of bitter taste. this gene codes for a g protein that is associated with a flavor receptor regulated by phenylthiocarbamide (ptc) and propylthiouracil (prop) ligands, which by binding to the receptor determines the degree of bitter taste. cruciferous vegetables contain glucosinolates and isothiocyanates, which resemble ptc and prop and thereby affect their perception of bitter taste through the tas2r38 regulated receptor. the polymorphism of this gene allows to distinguish three phenotypes: * insensitive to bitter taste \[bitter-non tasters\] * moderately sensitive to bitter taste \[intermediate-bitter tasters\] * sensitive to bitter taste \[bitter taster\] previous studies have shown that people who are carriers of one pav haplotype experience a bitter taste more than avi / avi homozygotes, which are less sensitive to bitter taste. hence, the tas2r38 gene polymorphism is associated with nutritional decisions, including choice of vegetables and coffee. aim of the study is to verify effectiveness of the genotype based dietary intervention in people with or without polymorphism of tas2r38 gene.

Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * injuries, chronic diseases (e.g. diabetes, metabolic syndrome, cancer, hyperthyroidism), recent diet, pregnancy, breastfeeding, limited communication to the extent that no nutritional history can be carried out, eating disorders (according to nutritional history)

Keywords: tas2r38 polymorphism bitter taste pav avi vegetables personalized nutrition genotype intake fruit and vegetables
bone and joint infections - simplifying treatment in children trial

Conditions: Bone Infection; Septic Arthritis; Bone and Joint Infection; Osteomyelitis

Summary: this is a multi- centre trial of children with bone and joint infections (bjis) at eight major paediatric hospitals in australia and new zealand. the primary objective is to establish if in children with acute, uncomplicated bjis, entirely oral antibiotic treatment is not inferior to initial intravenous (iv) treatment for 1 to 7 days followed by an oral antibiotic course in achieving full recovery 3 months after presentation. children will be randomly allocated to the 'entirely oral antibiotic' group or the 'standard treatment' group.

children with acute onset bjis who present to the participating sites will be enrolled into the trial if eligible (see eligibility criteria) and randomly allocated into two groups. children in the 'standard treatment group' will receive standard treatment for bjis, which consists of iv antibiotics for 1-7 days followed by 3 weeks of oral antibiotics. children in the 'entirely oral treatment group' will receive high dose oral antibiotics, followed by the standard dose of oral antibiotics for 3 weeks. the outcomes of children in each of the two groups will be compared to determine whether bjis can be treated without needing a course of iv antibiotics.

Eligibility criteria:
inclusion criteria: * children aged 1 to 18 years with acute, uncomplicated, community-acquired bone and joint infection who fulfil pre-defined clinical criteria. exclusion criteria: 1. infection due to bacteria resistant to cefalexin or atypical infection (e.g. mycobacterial, fungal) 2. features of sepsis as defined by the presence of organ dysfunction (defined using definitions within the pediatric logistic organ dysfunction-2 (pelod-2) score) 3. concomitant severe, invasive infection e.g. necrosing fasciitis 4. complicated infection (e.g. presence of prosthetic material; large subperiosteal (\>3mm) or soft tissue abscess without surgical intervention; infection secondary to or complicated by trauma) 5. history of allergy to cephalosporin antibiotics or immediate, severe reaction to penicillins 6. received more than three iv or oral dose of an antibiotic with activity against the likely bacteria causing the current infection 7. prior episode of om or sa 8. prior condition predisposing to poor absorption (e.g. inflammatory bowel disease, current gastrointestinal symptoms) or complicated disease (e.g. immunodeficiency) 9. prior enrolment in the trial 10. current recipient of another investigational product as part of a clinical trial
pragmatic trial comparing weight gain in children with autism taking risperidone versus aripiprazole

Conditions: Weight Gain; Autism Spectrum Disorder; Medication Side Effect

Summary: this study aims to compare two fda approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders. this trial, done in the context of routine clinical care, will seek to evaluate whether aripiprazole or risperidone is associated with more weight gain in children.

autism is a developmental disability with increasing prevalence in our society. currently one out of fifty-nine children in the united states has this condition. many children with autism experience behavioral dysregulation such as irritability and aggression. currently, there are two fda approved atypical antipsychotic medications that treat irritability in children with autism. these are aripiprazole and risperidone. while it is thought that aripiprazole may cause less weight gain than risperidone, clinically this has not been proven. understanding the relative risk of atap-induced weight gain that results from risperidone versus aripiprazole in a real-world setting could help guide the choice of medical intervention and reduce the cardiometabolic risks, and, most critically, address the limitations of current studies, which have not been able to provide clear clinical insights given the difficulty with having a representative and robust number of patients enrolled. to be enrolled in this study, participants must be younger than 18 years of age, on the autism spectrum, have behavioral dysregulation, be naive to treatment with atypical antipsychotics and be seen either in the division of developmental medicine or child and adolescent psychiatry at vanderbilt university medical center. for enrolled patients, the ordering provider will see an order set, randomized to either aripiprazole or risperidone. they will then choose the recommended antipsychotic that the patient has been randomized to, or override the prompt. if the provider overrides the prompt, they will be asked to provide a reason for not choosing the recommended option. the outcome measure for this study will be weight gain at a 3 month follow-up visit.

Eligibility criteria:
inclusion criteria: * age 17 years and younger * diagnosed with autism * have behavior problems * seen in vanderbilt clinic * naïve to atypical antipsychotics exclusion criteria: * 18 years or older * history of atypical antipsychotic use * not diagnosed with autism
rotational thromboelastometry versus dic score in sepsis

Conditions: Sepsis; Septic Shock

Summary: sepsis results in activation of the coagulation system, which is commonly described as disseminated intravascular coagulation (dic). the dic score, which is commonly used to define this syndrome, does not allow to delineate between hypercoagulation and hypocoagulation. the aim of this prospective observational study is to evaluate data from automated rotational thromboelastometry and compare these with the dic score regarding intensive care unit outcome.

sepsis results in an intensive interaction between inflammation and the coagulation system. the activation of the coagulation system leads to consumption of procoagulatory as well as anticoagulatory proteins and platelets. this process may induce microcirculatory thrombosis as well as hemorrhagic diathesis, which is commonly described as disseminated intravascular coagulation (dic). the international society on thrombosis and haemostasis (isth) recommends the use of the dic score to describe this syndrome. a score of at least 5 points is defined as an overt dic. however, the dic score does not allow to differentiate between a hypercoagulation and hypocoagulation states and whether there could be a difference regarding outcome between the two states. in this prospective observational study, patients admitted to a medical intensive care unit will be included. the dic score as well as rotational thromboelastometry (rotem) will be evaluated within the first 24 hours after the diagnosis of sepsis as well as on day 3 and 5.

Eligibility criteria:
inclusion criteria: * sepsis, defined according to the sepsis-3 definition * informed consent exclusion criteria: * age \<18 years * pregnancy and lactation * known coagulation disorder prior to admission for sepsis * known cirrhosis of the liver * known active malignancy * surgical procedure during the last 4 weeks * refusal to participate in the study

Keywords: sepsis septic shock disseminated intravascular coagulation rotational thromboelastometry dic score
performance of somofilcon a over one week in wearers adapted to omafilcon a

Conditions: Myopia

Summary: the objective of the study is to determine if habitual or adapted contact lens wearers of omafilcon a can be confidently refit into somofilcon a lenses and be successful after one week of daily wear. the primary outcome variables for this study are: * investigator responses to refit questions; * lens fit.

this is a prospective, single-site, dispensing, bilateral wear, open label, daily wear switch study, with the test lens (somofilcon a) being worn for 7 (+5) days.

Eligibility criteria:
inclusion criteria: * is at least 17 years of age and has full legal capacity to volunteer; * has read and signed an information consent letter; * is willing and able to follow instructions and maintain the appointment schedule; * habitually wears soft spherical contact lenses with a power between +6.00 to -10.00d (inclusive) for a minimum 5 days per week, 10 hours per day and anticipates no difficulty wearing contact lenses for 7 days per week, 10 hours per day; * habitually wears, or is able to be adequately refit into proclear 1 day lenses; * demonstrates an acceptable fit with proclear 1 day and clariti 1 day contact lenses; * is correctable to a visual acuity of 0.20 logmar (approximately 20/30) or better (in each eye) with the study lenses or habitual correction; * manifest cylindrical spectacle refraction does not exceed -1.00dc in either eye. exclusion criteria: * is participating in any concurrent clinical research study; * has any known active\* ocular disease and/or infection; * has a systemic condition that in the opinion of the investigator may affect a study outcome variable; * is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; * has known sensitivity to the diagnostic pharmaceuticals to be used in the study; * is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal communication); * is aphakic; * has undergone refractive error surgery; * is an employee of the centre for contact lens research; * has taken part in another clinical or (pharmaceutical) research study within the last 7 days.
long-term immunogenicity of the hiv gp120-neftat/as01b vaccine (gsk sb732461)

Conditions: Infection, Human Immunodeficiency Virus; HIV Infections

Summary: the purpose of this study is to evaluate the long-term persistence of binding antibody responses against v1v2 and gp120 in subjects who were vaccinated with the envelope glycoprotein 120 (gp120)-negative factor (nef)tat/ adjuvant system 01b (as01b) (gsksb732461) vaccine candidate. other immune parameters like the hiv-specific cluster of differentiation (cd4+) t cell and cd8+ t cell responses will also be evaluated.

glaxosmithkline (gsk) contributes to the public-private pox-protein partnership (p5) which is currently assessing the safety, immunogenicity and clinical efficacy of a prime-boost regimen aimed at preventing hiv transmission (http://www.hvtn.org/en.html). the booster component of the candidate vaccine used in this program consists of two gp120 clade c proteins administered with an adjuvant. in order to inform the selection of the adjuvant in future studies, data on long-term persistence of immunity after vaccination with gp120/as01 would prove useful. the present study was designed to address this question using a cohort of volunteers vaccinated several years ago with a candidate vaccine containing gp120 and as01.

Eligibility criteria:
inclusion criteria: * subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * written informed consent obtained from the subject prior to performing any study specific procedure. * a subject who has received at least 3 doses of the gp120-neftat/as01b (gsksb732461) vaccine candidate in gsk biologicals-sponsored pro hiv-002 study. exclusion criteria: * use of any investigational or non-registered product during 30 days prior to study enrolment. * history of hiv-1 or hiv-2 infection. * participation to another clinical trial of an investigational hiv vaccine between study pro hiv-002 and the present study. * chronic administration of immunosuppressants or other immune-modifying drugs during the period starting one month preceding this study. for corticosteroids, this will mean prednisone higher than or equal to (≥) 20 mg/day . inhaled and topical steroids are allowed. * administration of cytotoxic medication within 6 months preceding this study. * history of daily, long-term immunosuppressive medication between study pro hiv-002 and the present study. * administration of immunoglobulins and/or any blood products during the period starting 3 months before enrolment. * any confirmed or suspected immunosuppressive or immunodeficient condition other than hiv disease, based on medical history and physical examination between study pro hiv-002 and the present study. * past administration of an investigational vaccine containing as01 other than the gp120-neftat/as01b (gsksb732461) vaccine administered in pro hiv-002 study.

Keywords: gp120 hiv infections rv144 gp120-neftat/as01b vaccine candidate v1v2
target behaviours to identify minimally conscious state patients

Conditions: Disorder of Consciousness; Minimally Conscious State

Summary: to analyse the frequency of the consciousness behaviour response for patients with minimally conscious state of coma recovery scale-revised items, as well as the necessary items for obtaining higher accuracy. in addition, providing target behaviours for coma recovery scale-revised assessment of minimally conscious state diagnosis and evidence for the simplification of coma recovery scale-revised in the future.

data were collected according to the coma recovery scale-revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). all participants were diagnosed by using coma recovery scale-revised five times at least within 7 days. according to the results of the coma recovery scale-revised assessment, minimally conscious state and unresponsive wakefulness syndrome patients were distinguished.

Eligibility criteria:
inclusion criteria: * patients with medical diagnosis of prolonged disorders of consciuosness (≥28 days) were included in neurosurgery, neurology, and neurorehabilitation units. exclusion criteria: * patients who used neuromuscular blockers or sedatives within 72 hours of enrolment were excluded.

Keywords: disorders of consciousness coma recovery scale-revision minimally conscious state
relation between bruxism and cervical function

Conditions: Bruxism

Summary: correlation between bruxism and cervical function

bruxism is defined as an unconscious oral habit of dysfunctional rhythmic pressing, clenching and grinding of the teeth when performing movements that are not part of the masticatory function that leads to occlusal trauma and it is an oral parafunctional activity it is not related to normal physiological functions, such as speech, breathing, chewing and swallowing , and/or by bracing or thrusting of the mandible , and it accelerates abnormal tooth wear, periodontal disease, and temporomandibular disorders (tmd) bruxism should be considered a potential protective risk factor rather than a disorder in otherwise healthy individuals. in most persons bruxism is not a disorder, it is a sign of a disorder (e.g. in individuals with obstructive sleep apnea, epilepsy , being the ending episode of respiratory arousals, so as to prevent the collapse or restore the patency of the upper airway whilst asleep) , which would classify bruxism as an attribute that decreases the chance of a negative health outcome. there is two distinct circadian manifestations, either occurring during wakefulness or during sleep. awake bruxism is a semivoluntary masticatory muscle activity during wakefulness that is characterized clenching or grinding tooth and/or by bracing or thrusting of the mandible

Eligibility criteria:
inclusion criteria: * tooth-grinding or clenching . * sounds associated with bruxism or jaw muscle discomfort. * pain in the jaw, temple, ear or front of the ear and pain modified by jaw movement, function, or parafunction. exclusion criteria: * history of trauma to the face . * history of orthodontic treatment, craniofacial anomalies, degenerative disease, or tmj trauma . * any systematic joint or muscle disease and neurologic disorder. neurologic disorders (eg, trigeminal neuralgi ,neurologic disorders (eg, trigeminal neuralgi neurologic disorders (eg, trigeminal neuralgi * osteoarthrosis or arthritis of temporomandibular joint . * tumors in the head and neck area.

Keywords: bruxism cervical pain cervical proprioception